NCT02078609View on ClinicalTrials.gov

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 20, 2014

Primary Completion Date

April 18, 2019

Study Completion Date

April 18, 2019

Conditions
AML and High Risk MDS
Interventions
DRUG

LGH447

LGH447 in patients with AML or MDS

DRUG

LGH447 + midostaurin

LGH447 + midostaurin in patients with AML

Trial Locations (9)

3181

Novartis Investigative Site, Prahran

13273

Novartis Investigative Site, Marseille

20132

Novartis Investigative Site, Milan

20162

Novartis Investigative Site, Milan

48109

Novartis Investigative Site, Ann Arbor

89081

Novartis Investigative Site, Ulm

00133

Novartis Investigative Site, Roma

141 8625

Novartis Investigative Site, Shinagawa Ku

1081 HV

Novartis Investigative Site, Amsterdam

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY